Jinan Zhuocheng Bio-Tech Co., Ltd.

Recently, Solara Active Pharma Sciences Limited announced during its Q4 FY2026 earnings conference call that the company has formally engaged an investment bank to conduct a comprehensive strategic review of its ibuprofen business. The review includes the potential divestment of the asset, with a decision expected to be finalized within the next two quarters.

This move reflects Solara’s ongoing strategy to streamline its business portfolio and focus on core, high-margin operations.

Continued Pressure from Ibuprofen Operations

The company’s ibuprofen segment has been a persistent drag on overall profitability.

In Q4 FY2026, the segment generated revenue of INR 849 million, representing a 61% year-on-year increase, but still recorded a negative EBITDA of INR 179 million. For the full fiscal year, the segment posted an EBITDA loss of INR 527 million, significantly impacting the company’s overall earnings performance.

Structural Challenges: Cost and Technology Limitations

According to the company, the underperformance of the ibuprofen business is primarily driven by structural disadvantages in both cost and technology.

The segment lacks upstream integration, with its key starting material (IBAP) fully dependent on external procurement. In addition, the company does not possess industry-leading manufacturing processes, resulting in relatively higher production costs.

Against the backdrop of sustained price pressure and an oligopolistic global ibuprofen market structure, the business has limited prospects for near-term profitability improvement.

Stable Performance of Core Business

In contrast, Solara’s core business continues to deliver stable performance, with an EBITDA margin of approximately 26% and a gross margin of around 54%, serving as the company’s primary driver of revenue and profitability.

The company emphasized that reallocating resources away from loss-making segments toward high-margin core operations is a rational strategic priority.

Strategic Options Under Evaluation

Solara is currently evaluating two primary strategic alternatives:

First, the potential sale of the ibuprofen business to a buyer with stronger operational capabilities; this remains the company’s preferred option.

Second, the conversion of dedicated ibuprofen manufacturing assets into multipurpose production facilities to improve asset utilization and flexibility.

To support this review process, the company has temporarily paused its planned spin-off of its polymers and CRAMS businesses until a final decision on the ibuprofen strategy is made.

Management also stated that it will engage in proactive communication with customers of the ibuprofen business to ensure supply continuity and minimize any disruption to non-ibuprofen clients.

Industry Context

According to industry data, ibuprofen export prices in both India and China have shown a declining trend from 2021 through February 2026, with Indian export prices slightly below those of China.

Among major global ibuprofen manufacturers—including 新华制药, 亨迪药业, IOL Chemicals and Pharmaceuticals Limited, and Solara—companies with integrated upstream-intermediate-API supply chains, such as Xinhua and IOL, have demonstrated stronger cost competitiveness and lower export pricing.

In contrast, Solara’s relatively higher cost structure, driven by limited upstream integration and less advanced manufacturing processes, has resulted in higher pricing and sustained margin pressure during the industry downcycle.

Outlook

Solara expects to announce the final outcome of its strategic review in the first half of FY2027, with all developments to be disclosed through official company communications and stock exchange filings.